Beckman Coulter and MeMed to expand access to proven host immune response diagnostic able to distinguish between bacterial and viral infections
Beckman Coulter Diagnostics and MeMed announced a strategic partnership to jointly develop and commercialize the proven MeMed BV test, a host immune response diagnostic that is able to distinguish between bacterial and viral infections for use on the Access Family of Immunoassay Analyzers.
MeMed BV is a diagnostic test developed to address management of patients with acute infection in different clinical settings, including Emergency Departments. The MeMed BV test uses machine learning to integrate measurements of three key host-immune proteins (TRAIL, IP-10, and CRP) into a score indicating the likelihood of bacterial or viral infections. This performance has been validated on MeMed’s compact immunoassay platform (MeMed Key) by world class institutions in multi-national blinded validation studies as well as in real-world use, altogether in over 20,000 patients. MeMed BV on MeMed Key is US FDA cleared, CE-Marked and approved by the Israeli Ministry of Health.
Under the terms of the agreement, Beckman Coulter has obtained the rights to develop and co-promote the proprietary MeMed BV test on its Access Family of Immunoassay Analyzers.
